de Silva, H.J.Dassanayake, A.S.Manamperi, A.de Silva, A.P.2014-10-292014-10-292006Transplantation Proceedings. 2006; 38(9): 3118-1200041-1345 (Print)1873-2623 (Electronic)http://repository.kln.ac.lk/handle/123456789/1711Indexed in MEDLINEWe report the treatment outcome in six post-renal transplant patients with lamivudine-resistant hepatitis B virus (LR-HBV) infection using adefovir dipivoxil and followed for 6 to 18 months. Posttransplant immunosuppressive therapy was not altered. Adefovir dipivoxil effectively suppressed hepatitis B virus DNA and improved alanine transferase, although DNA suppression seemed dependent on continued therapy. Nephrotoxicity led to withdrawal of the drug in three patients. This may limit therapeutic usefulness in a significant proportion of post-renal transplant patients with LR-HBV infection.ArticleMedicinePharmacologyMMU